https://www.thebodypro.com/category/fda-approved-hiv-medications

FDA-Approved HIV Medications

The Latest

hole in a fence
News

This Week in HIV Research: Removing Barriers to Better Care

Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.

Customer giving medical prescription to pharmacist
News Analysis

What Needs to Happen Before California Pharmacies Can Sell PrEP and PEP Without an Initial Prescription

Pharmacists will increasingly play a role in pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) access in California.

pregnant woman talking to doctor
Conference Coverage

Raltegravir Not Linked to Birth Defects, Study Shows

Amidst uncertainty regarding the safety of some integrase inhibitors during pregnancy, a study shows that an older integrase inhibitor may be a good option for those with HIV who intend to give birth.

Pair of female feet on a bathroom scale
Conference Coverage

One Class of HIV Drugs Is Associated With Weight Gain. What's the Latest?

The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.

young man looking at pill before taking it
News

FDA Approves Descovy for PrEP, but Only for Cisgender Men and Transgender Women

The FDA approved the fixed-dose combination of emtricitabine and tenofovir alafenamide for PrEP, but advocates hope to see more research on the HIV prevention drug's efficacy for receptive vaginal sex for cisgender women and transgender men.

close up of man's hands counting money
Viewpoints

HIV Organizations and Workers Should Routinely Disclose Ties to Pharma Industry

Improve the funding, control the potential conflicts of interest.

woman with doctor looking at prescription bottle
News

This Week in HIV Research: Every Prescription Can Use a Good Steward

Sept. 19, 2019: HIV antiretroviral stewardship plans in hospitals can save money -- and lives; demographic correlates of PrEP interruption; HIV and atrial fibrillation risk; cytopenias common, despite viral suppression.

Conference Centre at 10th IAS Conference on HIV Science (IAS 2019), Mexico City, Mexico
Conference Coverage

Does Descovy Really Work Better Than Truvada for PrEP? One Researcher Raises Questions About the DISCOVER Trial Results

Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.

Christoph D. Spinner
Conference Coverage

DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

Fernanda Fernandes Fonseca and Meg Doherty at an IAS 2019 press conference
News

World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.